Cover Image

Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease affecting more than 1% of the population over 65 years old. The etiology of the disease is unknown and there are only symptomatic managements available with no known disease-modifying tre...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kai-Jung Lin (Author), Tzu-Jou Wang (Author), Shang-Der Chen (Author), Kai-Lieh Lin (Author), Chia-Wei Liou (Author), Min-Yu Lan (Author), Yao-Chung Chuang (Author), Jiin-Haur Chuang (Author), Pei-Wen Wang (Author), Jong-Jer Lee (Author), Feng-Sheng Wang (Author), Hung-Yu Lin (Author), Tsu-Kung Lin (Author)
Format:	Book
Published:	MDPI AG, 2021-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice
by: Chao-Cheng Huang, et al.
Published: (2015)

Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study
by: Mar Garcia Zamora, et al.
Published: (2024)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018)

Seizure-Induced Oxidative Stress in Status Epilepticus: Is Antioxidant Beneficial?
by: Tsu-Kung Lin, et al.
Published: (2020)

Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate
by: Kayla Chonko, et al.
Published: (2023)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
by: Lingxiang Xie, et al.
Published: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
by: Mohammed Aldhaeefi, et al.
Published: (2023)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice
by: Atsuo Tahara, et al.
Published: (2016)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020)

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
by: Mobin Mohammadtabar, et al.
Published: (2023)

Sotagliflozin, an inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018)

Sotagliflozin, an inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018)

HIV drug nucleoside reverse transcriptase inhibitors as promising anti-inflammation therapeutics by targeting P2X7-dependent large pore formation: one stone for two birds?
by: Lin-Hua eJiang
Published: (2015)

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin-Nicotinamide-Induced Mildly Diabetic Mice
by: Atsuo Tahara, et al.
Published: (2012)

One stone to kill two birds
Published: (2009)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study
by: Yilong Lin, et al.
Published: (2024)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021)

Development and optimization of amphiphilic self-assembly into nanostructured liquid crystals for transdermal delivery of an antidiabetic SGLT2 inhibitor
by: Nancy M. Lotfy, et al.
Published: (2022)

Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023)

The Management of Diabetes with Hyperuricemia: Can We Hit Two Birds with One Stone?
by: Wang Y, et al.
Published: (2023)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018)

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
by: Yen-Chieh Lee, et al.
Published: (2022)

Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
by: Alicia Swee Yan Yip, et al.
Published: (2022)

Autonomic modulation by SGLT2i or DPP4i in patients with diabetes favors cardiovascular outcomes as revealed by skin sympathetic nerve activity
by: Jien-Jiun Chen, et al.
Published: (2024)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022)

Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone
by: Luxi Yang, et al.
Published: (2021)

Interleukin-33 promotes invasiveness of human ovarian endometriotic stromal cells through the ST2/MAPK/MMP-9 pathway activated by 17β-estradiol
by: Ta-Chin Lin, et al.
Published: (2021)

Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure
by: Ya-Wen Lin PhD, RN, et al.
Published: (2024)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

Glycaemia and body weight are regulated by sodium-glucose cotransporter 1 (SGLT1) expression via O-GlcNAcylation in the intestine
by: Kimihiro Nishimura, et al.
Published: (2022)

Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
by: Min Sun, et al.
Published: (2024)

Role of NLRP3 Inflammasome in Heart Failure Patients Undergoing Cardiac Surgery as a Potential Determinant of Postoperative Atrial Fibrillation and Remodeling: Is SGLT2 Cotransporter Inhibition an Alternative for Cardioprotection?
by: Rodrigo L. Castillo, et al.
Published: (2024)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
by: Li-Min Zhao, et al.
Published: (2022)

Stone Throwing in the Glass House
by: James Anthony Lin
Published: (2016)

Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis
by: Qian Wang, et al.
Published: (2024)

One stone two birds: anti-inflammatory bronchodilators as a potential pharmacological strategy for COVID-19
by: Yuanyuan Yu, et al.
Published: (2023)